Additionally, we demonstrate that Menin inhibition single treatment is sufficient for suppressing NUP98-r AML in the presence of concomitant mutations such as FLT3-ITD and WT1; however, the combination of Menin and FLT3 inhibitors significantly reduce the antileukemic efficacy of each agent. The gene discussed is FLT3; the disease is acute myeloid leukemia.